Home » Stocks » UNCY

Unicycive Therapeutics, Inc. (UNCY)

Stock Price: $3.03 USD 0.12 (4.12%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
After-hours: $3.16 +0.13 (4.29%) Jul 27, 7:59 PM
Market Cap 40.29M
Revenue (ttm) n/a
Net Income (ttm) -2.89M
Shares Out 13.30M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $3.03
Previous Close $2.91
Change ($) 0.12
Change (%) 4.12%
Day's Open 2.77
Day's Range 2.64 - 3.20
Day's Volume 2,380,303
52-Week Range 2.60 - 8.73

News

Unicycive Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

About UNCY

Unicycive Therapeutics is a biotechnology company dedicated to developing treatments for certain medical conditions. Our current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us from, Spectrum Pharmaceuticals (“Spectrum”) and Sphaera Pharmaceuticals, respectively. Spectrum conducted a Phase 1 clinical tria... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Jul 13, 2021
CEO
Shalabh Gupta, M.D.
Employees
1
Stock Exchange
NASDAQ
Ticker Symbol
UNCY
Full Company Profile

Financial Performance

Financial Statements